Abstract: Scientific advances have propelled the market for EPA and DHA omega-3s to high growth rates and a significant size for consumer products by increasing media exposure and authoritative recommendations on the benefits of omega-3s. There are no signs that the rate of scientific advancement is slowing, which should continue to support the market and continue to lead to greater penetration in sectors like functional foods. The industry has acted proactively to set high standards to enable the market's growth, and with significant investments into new sources of EPA and DHA, these standards will become even more important. Significant structural changes in the supply side of the market appear to be on the horizon both from the new sources and from the increasing demand for crude fish oils reaching the limits of available supply. Ultimately, economics will decide how the market evolves over the next 5 to 10 years.
The market for products containing EPA and DHA omega-3s has grown rapidly in recent years, more than quadrupling in size since 2001. GOED and Frost & Sullivan estimate that globally more than 86,000 tons of finished oils containing EPA and DHA were consumed in 2009. This translates into nearly US$13.1 billion in consumer expenditures on long-chain omega-3 products in multiple applications, and approximately US$1.29 billion in ingredient sales of refined oils and concentrated omega-3s (Frost & Sullivan, 2010) . The most common sources of EPA and DHA for consumers are often thought to be seafood and fish oil supplements, but the market has evolved significantly. Today, 17% of the global consumption of the fats comes from fortified foods, another 12% in infant and clinical nutrition, and 6% come even from pharmaceuticals (Frost & Sullivan, 2010) . In fact, last year, the first "blockbuster" drug milestone was reached with sales of the Lovaza/Omacor product from Pronova reaching US$1 billion in sales (Pronova Biopharma, 2010) . The growth in the body of science has driven the growth in sales of omega-3s. While data is not available in all geographies, sales of omega-3 dietary supplements in the US are correlated with the number of new scientific papers published each year on EPA and DHA, as can be seen in figure 1 . In fact, the correlation is so strong, the R-squared statistic indicates that the number of new papers published explains 92% of the sales increase each year. This is important for predicting future market growth because a search of the PubMed database shows that the pace of new publication is actually increasing, 1 9 7 9 1 9 8 0 1 9 8 1 1 9 8 2 1 9 8 3 1 9 8 4 1 9 8 5 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 Papers RCTs 6,000 4,000 2,000 0 1 9 7 9 1 9 8 0 1 9 8 1 1 9 8 2 1 9 8 3 1 9 8 4 1 9 8 5 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 2 0 0 2 2 0 0 3 2 0 0 4 2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9
Media stories Scientific papers We hypothesize that the mechanism by which new scientific publication leads to increased market growth of omega-3s is by the new papers leading to increased media exposure in the form of stories in consumer media outlets. This effect is both short-term and long-term in that consumer media stories are immediately written when new research comes out, but the steady flow of new publication also leads to a greater share of mind from consumer health editors, as can be seen in figure 2 . Additionally, the new volumes of research being published on the scale of omega-3s also leads to greater recognition by regulatory authorities in the form of new health claims being authorized and intake recommendations being established. While this effect logically lags the media effect in terms of market impact, it also leads to additional media exposure both from national public health campaigns and from the newsworthiness of new health recommendations being established. Indeed, consumer awareness of omega-3s has increased steadily over time. lishing its search data for public consumption. Indeed, searches for omega-3 terms correlate to omega-3 dietary supplement sales with an R-squared statistic of 0.98 using data through 2008, as is shown in figure 3 . In fact, using this relationship to forecast 2009 sales indicates that sales of omega-3 supplements actually exceeded US$1 billion last year. While the market has grown on the back of science, there are variables common in consumer products that could threaten to decouple this relationship. The industry has been proactive in trying to prevent many of these events by collaborating over eight years ago to establish minimum quality standards based on the strictest aspects of regulations from geographies around the world, as is shown in figure 4 . The industry's voluntary adoption of these standards has led to increased globalization of supply and prevented any significant food safety incidents like those that have affected other nutraceutical markets. The effect of the strong market growth in traditional categories has been the incorporation of EPA and DHA into other categories like functional foods. The early market for EPA and DHA functional foods was dominated by products like spreads and yogurts that are friendlier to lipids needing protection from oxidative factors. However, the technological advances have moved the market forward greatly, and EPA and DHA can now be found in canned foods, baked goods, soft drinks, and confections, and in dozens of other food categories.
More importantly, this has been accomplished at higher dosages than are commonly perceived. In fact, there are some baked goods that have been fortified with omega-3 dosages at levels equivalent to 10 fish oil capsules. Many authoritative bodies have begun to recommend that consumers should get a minimum of 250 mg of EPA and DHA per day, and the high levels of fortification that are now achievable make it relatively easy to reach these dietary targets through fortified foods, as can be seen in figure 5 . Furthermore, multiple omega-3 functional foods have reached high levels of commercial success, which is a challenge for functional foods in general. Another function of the market growth has been the commercialization of new sources of EPA and DHA. Fish is the most recognized source of the fatty acids by consumers, but algae have been used for nearly two decades to produce oils high in DHA. There is currently work being conducted to commercialize algal sources that also contain high levels of EPA, and now a fungal source of EPA has also been launched commercially. In addition, more marine sources are being commercialized as well, including krill oils, green lipped mussel extracts, and squid oils. Economics is a key driving factor in the success of each source, so significant investments have been made into genetically modified oilseeds capable of producing long-chain omega-3s. No genetically modified plant sources are fully commercial yet, but the prospect of oilseed economics being introduced into the market could change the landscape dramatically. Even without the prospect of alternative sources being introduced, there are also structural changes on the horizon in the fish oil supply sector. The most widely used species of fish for omega-3 oils are the ones with the highest levels of EPA and DHA, which are largely the South American anchovy fisheries that contain approximately 30% EPA+DHA content. The 86,000 tons of refined fish oils being consumed in the world actually equates to approximately 130,000 metric tons of crude fish oils due to yield losses, according to GOED's estimates. The challenge is that the South American fisheries are typically capable of supplying approximately 300,000 metric tons of oils in any given year based on the catch allowed under Peruvian regulations to ensure a sustainable fishery. This means that if the market continues growing as fast as it has in recent years, then the available supply of oils from the South American anchovy fishery will not be sufficient to supply the demand for all omega-3 applications by as early as 2013. The implication of this is that the more price-sensitive applications for omega-3 oils, like pet foods and dietary supplements, will be forced to find other sources of EPA and DHA while the least price-sensitive categories, like pharmaceuticals, will be forced to pay more for oil but will still have access to supply.
